67 results
424B5
STRO
Sutro Biopharma Inc
12 May 20
Prospectus supplement for primary offering
5:02pm
properties to maximize safety and efficacy for this promising class of cancer therapeutics.
Recent Developments
Impacts of the COVID-19 Pandemic … , all of which are uncertain and cannot be predicted. The COVID-19 pandemic and its adverse effects have become more prevalent in the locations where we
424B5
STRO
Sutro Biopharma Inc
11 May 20
Prospectus supplement for primary offering
4:12pm
-19 Pandemic
The extent of the impact of COVID-19 on our operational and financial performance will depend on certain developments, including … , suppliers and manufacturers, all of which are uncertain and cannot be predicted. The COVID-19 pandemic and its adverse effects have become more prevalent
8-K
EX-99.1
lt4ebdd7hl8r6t p33w
11 May 20
Sutro Biopharma Reports First Quarter 2020 Financial Results
4:27pm
8-K
EX-99.1
evtz18
18 Mar 21
Sutro Biopharma Reports Full Year 2020 Financial Results
7:00am
8-K
1ko38 dg9emf
30 Sep 21
Other Events
7:00am
8-K
EX-99.1
n12edi13974 39d2u
6 Aug 20
Sutro Biopharma Reports Second Quarter 2020 Financial Results
7:03am
8-K
yle7 xnwdmwj786z
26 Jul 22
Other Events
4:02pm
8-K
gtzriqd37vvy066 5a
15 Apr 21
Other Events
7:00am
8-K
wyr1ee01
7 Dec 20
Regulation FD Disclosure
3:45pm
8-K
8pwlzao6
4 Dec 20
Sutro Biopharma Announces Encouraging Interim Data on STRO-002 Phase 1 Dose-Escalation Study for Patients with Ovarian Cancer
12:00am
8-K
ssv03z7n4nsdvhsje
5 Jan 22
Sutro Biopharma Announces Interim Data from Dose-Expansion Cohort of STRO-002 Phase 1 Study for Patients with Advanced Ovarian Cancer
5:27pm
8-K
EX-99.1
k3wc sw59x6
4 Dec 20
Sutro Biopharma Announces Encouraging Interim Data on STRO-002 Phase 1 Dose-Escalation Study for Patients with Ovarian Cancer
12:00am
8-K
pejry8x mt
27 Apr 20
Sutro Biopharma Announces Encouraging Interim Phase 1 Clinical Data for a Dose Escalation Study of STRO-002 Antibody-Drug Conjugate in Ovarian Cancer
8:00am